Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) to Ring The Nasdaq Stock Market Closing Bell
April 16 2015 - 10:00AM
What:
Corbus Pharmaceuticals Holdings, Inc. (Nasdaq:CRBP), a clinical
stage drug development company focused on the development and
commercialization of treatments for rare, life-threatening
inflammatory and fibrotic diseases, will visit the Nasdaq
MarketSite in Times Square.
In honor of the occasion, Yuval Cohen, Ph.D., Chief
Executive Officer, will ring the Closing Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway –
Broadcast Studio
When:
Friday, April 17, 2015 – 3:45 p.m. to 4:00 p.m. ET
Corbus Pharmaceuticals Holdings, Inc. Media
Contact:David Schull or Marissa GoberdhanRusso Partners,
LLC+1 (858) 717-2310david.schull@russopartnersllc.com or
marissa.goberdhan@russopartnersllc.com
Nasdaq MarketSite:Christine Barna(646)
441-5310Christine.Barna@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West18 mhz LowerDL 3811 VerticalFEC
3/4SR 13.235DR 18.295411MOD 4:2:0DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo
postings, status updates and video of bell ceremonies please visit
our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram
Page: http://instagram.com/nasdaq
For news tweets, please visit our Twitter page
at: http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr
Page: http://nasdaq.tumblr.com/
Webcast:
A webcast of the Nasdaq Closing Bell will be available at:
https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Close, please
go to http://www.nasdaq.com/reference/marketsite_events.stm and
click on the market close of your choice.
About Corbus Pharmaceuticals Holdings,
Inc. (Nasdaq:CRBP):
Corbus Pharmaceuticals is a clinical stage pharmaceutical
company focused on the development and commercialization of novel
therapeutics to treat rare life-threatening inflammatory and
fibrotic diseases. The Company’s lead product candidate Resunab™ is
a novel oral drug that resolves chronic inflammation and
pro-fibrotic processes. Resunab is scheduled to commence Phase 2
clinical trials for the treatment of cystic fibrosis and diffuse
cutaneous systemic sclerosis (scleroderma) in 2015. For more
information, please visit www.CorbusPharma.com.
About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing,
exchange technology, listing, information and public company
services across six continents. Through its diverse portfolio of
solutions, Nasdaq enables customers to plan, optimize and execute
their business vision with confidence, using proven technologies
that provide transparency and insight for navigating today's global
capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 70
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to more than 3,500 listed companies
with a market value of approximately $9.5 trillion and more than
10,000 corporate clients. To learn more, visit: nasdaq.com/ambition
or business.nasdaq.com.
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Feb 2024 to Mar 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2023 to Mar 2024